Weibin WANG
2013-04-19 09:57:03   

Managing Partner, Lawyer, Patent Attorney, Trademark Attorney, Technology Broker
Practice Areas:
Patent Drafting; Office Action Responding; Patent Reexamination and Invalidation; FTO Analysis; Patent Administrative Litigation; IP Due Diligence; Settlement of Disuptes over Patent Ownership; Patent Infringement Litigation; Trade Secret Litigation; Trademark Protection Strategy; Trademark Litigation etc.
Technical Fields:
Organic Chemistry, Macromolecular materials, Fine Chemistry, Medicine, Food, Biology, Energy and Chemical Engineering
Working Languages: Mandarin Chinese; English
Shanghai University Law LL.M
Shanghai Institute of Materia Medica, CAS Medicinal Chemistry M.S.
Jilin University Chemical Engineering and Technology B.S
Oliff & Berridge PLC Training Course of US Patent Law  
Outstanding figures in the field of intellectual property services in Shanghai
——Shanghai Intellectual Property Service Industry Association
Service Star
——Shanghai Intellectual Property Magazine
Best Lecturer Silver Award
——Shanghai Intellectual Property Service Industry Association
Yangtze River Delta Intellectual Property Elite Award
-----Yangtze River Delta Intellectual Property Development Alliance
Top 10 Patent Agent
——Power-nation platform
Young Lawyer of the Year East China- Local (nominated)
——Asian Legal Business (ALB)
Yangtze River Delta Rising Lawyer
——Asian Legal Business (ALB)
Gold Trademark Service-Individuals
——China Trademark Association
ShanghaiTech University                                                    Enterprise Mentor
Patent Protection Association of China                                         CommissionerPatent Protection Association of China-Pharmaceutical Professional Committee        Commissioner
Special Plan for transformation of Shanghai Patent                               Patent Commissioner
Beijing Intellectual Property Law Society- Patent Law Committee                    Commissioner
Participation of IP-related organizations:
2014-present   Member of International Trademark Association (INTA)
2018-present   Member of International Association for the Protection of Intellectual Property (AIPPI)
Mr. Wang is taking charge of Foreign-Related Patent Department and Trademark and Copyright Department in our law firm. During 15-year practice, he has represented clients in nearly one thousand domestic patent applications and PCT filings, and in hundreds of overseas patent applications including patent for invention, utility model and design in many jurisdictions involve the United States, Japan, Europe, UK, South Korea, India, Canada, Australia, Southeast Asia, South America, Middle East, Africa etc. in the areas of chemistry, pharmaceuticals and biology. He has also represented clients in dozens of cases of patent re-examination.
He has also handled dozens of cases of patent invalidation, with a winning rate of over 80%. In cases of patent invalidation, he had acted as an agent for either petitioners or patentees (respondents).
In 2016, Mr. Wang was recognized as a star-level agent by China Intellectual Property News. He has also been recommended as a patent attorney of civil action and administrative litigation by ALL-China Patent Attorneys Association for many years which kept on record in the Supreme People’s Court of PRC.
In terms of contentious area, He successfully helped companies that involves Fortune Global 500 in the fields of chemical engineering, pharmaceuticals and materials handled many disputes over patent ligation in the fields of chemical engineering and pharmaceuticals, with a winning rate of over 80%, including litigation of patent invalidation and patent ownership, disputes over technical contracts, technical secret litigation and patent administrative litigation retried by the Supreme People’s Court of PRC.
In terms of non-contentious area, Mr. Wang has led teams to accomplish over ten large-scale FTO investigations and patentability analysis projects for celebrated companies in China, Germany and Australia in which the target counties and regions includes global areas and specific countries such as China, America, Japan, Russia and Indonesia. He has also led teams to help several well-known venture capital funds to conduct pre-investment intellectual property due diligence, evaluate or eliminate investment risks for the high-tech enterprises to be invested in.
In addition, Mr. Wang has been actively engaged in intellectual property training lectures and speeches in Chinese or English which are up to nearly one hundred. He was appointed twice by ALL-China Patent Attorneys Association as a training lecturer for the training class of Shanghai licensed/registered patent attorneys, was invited twice by Shanghai Intellectual Property Service Center to serve as a lecturer for the training class regarding improving the capabilities of Shanghai patent attorneys, had been invited as a lecturer for the training class of Shanghai patent practitioners for several consecutive years, and also had been invited to give a series of lectures for the masters of law in Shanghai International College of Intellectual Property, Tongji University. Moreover, he had carried out various training including basic knowledge of patents, patent mining, patent portfolios, FTO, due diligence, foreign-related patent practice, transfer or transformation of intellectual property etc. for many clients. The said lectures are all well received. In 2019, He was awarded “The Silver Award for Best Lecturers” by Shanghai Intellectual Property Service Association.
Mr. Wang had published many articles on intellectual property research in leading academic journals such as Chinese Journal of New Drugs, Progress in Pharmaceutical Sciences, SHANGQIN (Business) etc. He participated in the translation proofreading of US Patent Application Drafting and Prosecution Strategies which was published in 2017 by Intellectual Property Publishing House. As a deputy editor, he had led our team to write “Inventiveness” which was published in 2020 by Intellectual Property Publishing House.
Mr. Wang has counseled hundreds of clients including Henkel, Symrise, China National Pharmaceutical Group Corporation, Shanghai Pharmaceuticals Holding Co., Ltd., Shanghai Institute of Organic Chemistry, Shanghai Dongda Chemical Co., Ltd., Shanghai Institute of Pharmaceutical Industry, WuXi Apptec, Chempartner Co., Ltd., Zhejiang Hisun Pharmaceutical Co., Ltd., Humanwell Group, Ascentage Pharma, CSPC Pharmaceutical Group Co., Ltd. (CSPC), Fujian Cosunter Pharmaceutical Co., Ltd., BUCHANG PHARM, Guangdong Zhongsheng Pharmaceutical Co., Ltd., Zhejiang Yongning Pharmaceutical Co., Ltd., Fujian South Pharmaceutical Co., Ltd., Shanghai Shyndec Pharmaceutical Co., Ltd., Chinese and Western Pharmaceutical Co., Ltd., Allist, Lianhetech, AB Pharma, Viwit Pharmaceutical Co., Ltd., Hanhui Pharmaceutical Co., Ltd., Anrun Pharma, QR Pharmaceuticals, Kangpu Group, etc., which are well-known enterprises and institutions for the research and development of new drugs, generic drugs and pharmaceutical technology.